Biotage has signed an agreement to acquire all the outstanding shares of UK-based company ATDBio in a debt-free and cash-free…
20 Oct 2021
Amgen concludes acquisition of biotech company Teneobio for $2.5bn
Amgen has concluded the acquisition of all outstanding shares of clinical-stage biotechnology firm Teneobio in a deal worth $2.5bn. According to the previously announced agreement, Amgen paid $900m upfront in…
18 Oct 2021
Silence and Hansoh partner to develop siRNA-based treatments
Silence Therapeutics and Hansoh Pharmaceutical have entered a partnership to develop small-interfering ribonucleic acid (siRNAs) drugs for three undisclosed targets using the former’s mRNAi GOLD platform. Following the conclusion of…
12 Oct 2021
Pacira to acquire Flexion Therapeutics to boost non-opioid pain portfolio
Pacira BioSciences has entered a definitive agreement to acquire biopharmaceutical firm Flexion Therapeutics to boost its non-opioid pain portfolio. The company will acquire Flexion for an equity value of nearly…
12 Oct 2021
Supernus Pharmaceuticals signs agreement to acquire Adamas for $450m
Supernus Pharmaceuticals has signed an agreement for the acquisition of Adamas Pharmaceuticals for nearly $450m. Through this acquisition, Supernus will get access to Adamas’ two commercial products, Gocovri (amantadine) extended-release…
11 Oct 2021
Sandoz acquires cephalosporin antibiotics business of GSK
Novartis’ subsidiary Sandoz has completed its previously announced acquisition of GlaxoSmithKline’s (GSK) cephalosporin antibiotics business for $500m. This follows an agreement signed by the companies in February this year. The…
01 Oct 2021
Takeda and JCR Pharmaceuticals partner to market Hunter syndrome therapy
Takeda Pharmaceutical and JCR Pharmaceuticals have signed a partnership and license agreement to market JR-141 (pabinafusp alfa) for the treatment of Hunter syndrome (Mucopolysaccharidosis type II or MPS II). JR-141…
© Copyright Verdict Media Limited 2021
Powered by
